Showing results (121-130 of 138) with videos related to
Sort By:
Pageof 14
Plos Pathogens|August 25, 2018
Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replicationKrystelle Nganou-Makamdop, James M Billingsley, Zachary Yaffe, et al.Cell Host & Microbe|June 25, 2021
SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivityChihiro Motozono, Mako Toyoda, Jiri Zahradnik, et al.Iscience|December 12, 2022
The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variantIzumi Kimura, Daichi Yamasoba, Hesham Nasser, et al.Nature Microbiology|July 29, 2024
Engineering Toxoplasma gondii secretion systems for intracellular delivery of multiple large therapeutic proteins to neuronsShahar Bracha, Hannah J Johnson, Nicole A Pranckevicius, et al.Journal of Virology|October 5, 2023
Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristicsIzumi Kimura, Daichi Yamasoba, Hesham Nasser, et al.Biorxiv : the Preprint Server for Biology|July 28, 2023
RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airwaysMatthew Gagne, Barbara J Flynn, Christopher Cole Honeycutt, et al.New Biotechnology|October 19, 2010
"4D Biology for health and disease" workshop reportJan-Pieter Abrahams, Rolf Apweiler, Rudi Balling, et al.Nature Communications|August 12, 2024
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airwaysMatthew Gagne, Barbara J Flynn, Christopher Cole Honeycutt, et al.Nature Communications|May 11, 2023
Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variantJumpei Ito, Rigel Suzuki, Keiya Uriu, et al.Cell|October 5, 2022
Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5Izumi Kimura, Daichi Yamasoba, Tomokazu Tamura, et al.Pageof 14